Bioxyne Limited

Equities

BXN

AU000000BXN6

Biotechnology & Medical Research

Market Closed - Australian S.E. Other stock markets 01:31:42 2024-05-01 am EDT			5-day change	1st Jan Change
0.006 ^AUD	0.00%		-25.00%	-45.45%

Apr. 18	Bioxyne to Raise AU$1.45 Million via Share Issuance	MT
Feb. 29	Bioxyne Limited Reports Earnings Results for the Half Year Ended December 31, 2023	CI

Bioxyne Limited Reports Earnings Results for the Half Year Ended December 31, 2021

February 21, 2022 at 07:43 pm EST

Bioxyne Limited reported earnings results for the half year ended December 31, 2021. For the half year, the company reported net income was AUD 0.004562 million compared to net loss of AUD 0.284605 million a year ago.

Latest news about Bioxyne Limited

Bioxyne to Raise AU$1.45 Million via Share Issuance	Apr. 17	MT
Bioxyne Limited Reports Earnings Results for the Half Year Ended December 31, 2023	Feb. 28	CI
Bioxyne Receives License to Manufacture Medical Cannabis, MDMA; Shares Up 50%	Feb. 04	MT
Bioxyne Limited Announces Retirement of N H Chua as Director	Nov. 17	CI
Bioxyne Limited Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-31	CI
Bioxyne Unit Joins Forces to Launch B2B Cannabis Trading Platform in Australia; Shares Slump 11%	23-08-15	MT
Bioxyne Limited Extends Amazon Footprint into US and Japan	23-07-16	CI
Australian Shares Track Gains of Wall Street Peers Ahead of Inflation Data, Policy Meetings	23-06-13	MT
Bioxyne Launches Online Healthcare with Technology Partner InstantScripts; Shares Decline 8%	23-06-12	MT
Bioxyne Limited Appoints Jason Hine as Director	23-05-22	CI
Bioxyne Acquires Breathe Life Sciences	23-05-22	MT
Bioxyne Limited acquired Breathe Life Sciences Pty Ltd.	23-05-18	CI
Bioxyne Proceeds With Breathe Life Sciences Acquisition; Shares Fall 4%	23-03-19	MT
Bioxyne Limited Reports Earnings Results for the Half Year Ended December 31, 2022	23-02-23	CI
Bioxyne's Fiscal H1 Revenue Declines	23-01-27	MT
Bioxyne to Acquire Health, Wellness Peer Breathe Life Sciences; Shares Gain 4%	22-12-18	MT
Bioxyne Limited entered into a binding term Sheet to acquire Breathe Life Sciences Pty Ltd for AUD 32 million.	22-12-18	CI
Bioxyne Limited Announces Joining of Mr. Sam Watson the Board as Joint Chief Executive Officer	22-12-18	CI
Bioxyne Sells 49% Stake in Direct Selling Business	22-10-24	MT
Paramount Star Investments Limited reached agreement to acquire 49% of Direct Selling Business of Bioxyne Limited from Bioxyne Limited for $1 million.	22-10-23	CI
Bioxyne Limited Reports Earnings Results for the Full Year Ended June 30, 2022	22-08-29	CI
Bioxyne Limited Announces Board Changes	22-06-07	CI
Bioxyne Posts Higher Sales Revenue in First Nine-Months of FY22	22-04-27	MT
Bioxyne Limited Reports Earnings Results for the Half Year Ended December 31, 2021	22-02-21	CI
Bioxyne's Revenue Surges 12% in Half-Year Ended Dec. 31, 2021	22-01-31	MT

Chart Bioxyne Limited

Duration

Period

More charts

Company Profile

Bioxyne Limited is an Australia-based health and wellness products company. Its activity is the development, manufacture and distribution of nutritional health and wellness supplements through indirect wholesale and direct sales channels in the health and wellness sector. It is engaged in the consumer dietary supplements and functional foods markets through its probiotic, Lactobacillus fermentum VRI-003 (PCC). The Company has developed a range of functional food and beauty products containing ingredients sourced primarily from New Zealand, through its direct sales business trading as Bioxyne International. It has an interest in Breathe Life Sciences (BLS). It has operations across Australia, the United Kingdom, Japan, Europe and Southeast Asia with a health and wellness product portfolio, including health supplements, skincare, probiotics, cannabis-derived raw materials, starting materials, active pharmaceutical ingredients, cannabinoid-based therapies and telemedicine technology.

Sector

Biotechnology & Medical Research

Calendar

2024-08-27 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
BIOXYNE LIMITED	-45.45%	7.97M
IQVIA HOLDINGS INC.	+0.17%	42.19B
MODERNA, INC.	+10.92%	42.24B
LONZA GROUP AG	+44.30%	40.15B
CELLTRION, INC.	-6.20%	28.31B
ICON PUBLIC LIMITED COMPANY	+5.23%	24.63B
ALNYLAM PHARMACEUTICALS, INC.	-24.79%	18.2B
MEDPACE HOLDINGS, INC.	+26.69%	12.01B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.13%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.57%	10.4B

Other Biotechnology & Medical Research